It was recently shown that the PI3K inhibitors, copanlisib and duvelisib, are effective against DLBCL and relapsed/refractory T-cell lymphoma, respectively [17, 18]. Here, PIK3CB is linked to T-cell non-Hodgkin lymphoma.